» Articles » PMID: 29551751

Bone Turnover Markers After the Menopause: T-score Approach

Overview
Journal Bone
Date 2018 Mar 20
PMID 29551751
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

Bone turnover increases at the menopause and is associated with accelerated bone loss. However, it is not known to what extent there is an imbalance between the processes of bone resorption and bone formation, nor whether it is the rate of bone turnover or the bone balance that is most closely associated with the rate of bone loss. We studied 657 healthy women ages 20 to 79 from five European cities (the OPUS Study) and divided them into two premenopausal age groups, 20 to 29 (n=129), 30 to 39years (n=183), and three postmenopausal groups 1 to 10years (n=91), 11 to 20years (n=131) and 21+ years since menopause (n=123). We measured collagen type I C-telopeptide (CTX, a marker of bone resorption) and procollagen I N-propeptide (PINP, a marker of bone formation). We used these two markers to calculate the overall bone turnover and the difference between bone formation and resorption (bone balance) using the results from the women ages 30 to 39years to calculate a standardised score (T-score). We found that the CTX and PINP levels were higher in the women ages 20 to 29 and in the women in the three menopausal groups as compared to women ages 30 to 39years (p<0.001). For example, the CTX and PINP levels were 80 and 33% higher in women 1 to 10years since menopause as compared to women ages 30 to 39years. In this group of postmenopausal women, the bone turnover expressed as a T-score was 0.72 (0.57 to 0.88, 95%CI) and the bone balance was -0.37 (-0.59 to -0.16). There was greater rate of bone loss from the total hip in all the groups of women after the menopause compared to women before the menopause. We conclude that the bone loss after the menopause is associated with both an increase in bone turnover and a negative bone balance and that bone loss was most clearly associated with overall bone turnover.

Citing Articles

Trends and hotspots in research on osteoporosis and nutrition from 2004 to 2024: a bibliometric analysis.

Li M, Yu B, Yang H, He H, Li N, Lv A J Health Popul Nutr. 2024; 43(1):204.

PMID: 39616355 PMC: 11608503. DOI: 10.1186/s41043-024-00690-5.


Intersecting Paths: Unraveling the Complex Journey of Cancer to Bone Metastasis.

Arakil N, Akhund S, Elaasser B, Mohammad K Biomedicines. 2024; 12(5).

PMID: 38791037 PMC: 11117796. DOI: 10.3390/biomedicines12051075.


Changes in Collagen Type I C-Telopeptide and Procollagen Type I N-Terminal Propeptide During the Menopause Transition.

Shieh A, Karlamangla A, Gossiel F, Eastell R, Greendale G J Clin Endocrinol Metab. 2023; 109(6):1580-1589.

PMID: 38087944 PMC: 11099485. DOI: 10.1210/clinem/dgad727.


Serum levels of bone turnover markers including calculation of -scores: Data from a Dutch healthy reference cohort.

Siderius M, Arends S, Kobold A, Wagenmakers L, Koerts K, Spoorenberg A Bone Rep. 2023; 19:101724.

PMID: 38047270 PMC: 10690549. DOI: 10.1016/j.bonr.2023.101724.


Aconine attenuates osteoclast-mediated bone resorption and ferroptosis to improve osteoporosis via inhibiting NF-κB signaling.

Xue C, Luo H, Wang L, Deng Q, Kui W, Da W Front Endocrinol (Lausanne). 2023; 14:1234563.

PMID: 38034017 PMC: 10682992. DOI: 10.3389/fendo.2023.1234563.